703-1403

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2012-12-12

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Mild CHEST DISCOMFORT — outcome: RECOVERED/RESOLVED; onset 2012-12-15 (study day 4.0); relationship: PROBABLE

moderate assessed

Moderate DIARRHOEA — outcome: RECOVERED/RESOLVED; onset 2012-12-13 (study day 2.0); relationship: PROBABLE

moderate assessed

Moderate VOMITING — outcome: RECOVERED/RESOLVED; onset 2012-12-13 (study day 2.0); relationship: PROBABLE

moderate assessed

Moderate WEIGHT DECREASED — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-12 (study day 1.0); relationship: NONE

moderate assessed

Moderate WEIGHT DECREASED — outcome: RECOVERED/RESOLVED; onset 2012-12-12 (study day 1.0); relationship: NONE

Data queries

No data queries.